Zevra Therapeutics (ZVRA) Earnings Date, Estimates & Call Transcripts $9.50 +0.22 (+2.37%) As of 02:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Zevra Therapeutics Earnings Summary Zevra Therapeutics posted Q1 2025 earnings on May 13, 2025, reporting an EPS of -$0.06, which topped the consensus estimate of -$0.21 by $0.15. Quarterly revenue was reported to be $20.40 million, above analysts' expectations of $16.96 million. With a trailing EPS of -$0.21, Zevra Therapeutics' earnings are expected to grow next year, from ($1.95) to $0.20 per share. Latest Q1 Earnings DateMay. 13EstimatedConsensus EPS (May. 13) -$0.21 Actual EPS (May. 13) -$0.06 Beat By $0.15 Actual Revenue (May. 13) $20.40MQ1 2025 Earnings ResourcesQ1 2025 Earnings ReportConference Call Transcript & Audio Press Release (8-K) Quarterly Report (10-Q)Powered by Get Zevra Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Zevra Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataZVRA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ZVRA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Zevra Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20253-$0.24-$0.17-$0.21Q2 20253-$0.09$2.26$1.43Q3 20253-$0.06-$0.03-$0.05Q4 20253-$0.08-$0.01-$0.05 FY 2025 12 -$0.47 $2.05 $1.12 Q1 20261-$0.04-$0.04-$0.04Q2 20261$0.00$0.00$0.00Q3 20261$0.08$0.08$0.08Q4 20261$0.14$0.14$0.14 Zevra Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame Start Date End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025-$0.21-$0.06+$0.15-$0.06$16.96M$20.40M3/11/2025Q4 2024-$0.39-$0.67 -$0.28-$0.67$8.93M$12.00M11/12/2024Q3 2024-$0.44-$0.69 -$0.25-$0.69$5.04M$3.70M8/13/2024Q2 2024-$0.47-$0.48 -$0.01-$0.48$4.08M$4.45M5/8/2024Q1 2024-$0.49-$0.40+$0.09-$0.40$3.52M$3.43M3/28/2024Q4 2023-$0.20-$0.40 -$0.20-$0.40$13.35M$13.22M11/7/2023Q3 2023-$0.29-$0.40 -$0.11-$0.40$3.70M$2.90M Zevra Therapeutics Earnings - Frequently Asked Questions When did Zevra Therapeutics announce their last quarterly earnings? Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earning data on Tuesday, May 13, 2025. Learn more on ZVRA's earnings history. Did Zevra Therapeutics beat their earnings estimates last quarter? In the previous quarter, Zevra Therapeutics (NASDAQ:ZVRA) reported ($0.06) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.21) by $0.15. Learn more on analysts' earnings estimate vs. ZVRA's actual earnings. How can I listen to Zevra Therapeutics' earnings conference call? The conference call for Zevra Therapeutics' latest earnings report can be listened to online. Listen to Conference Call How can I read Zevra Therapeutics' conference call transcript? The conference call transcript for Zevra Therapeutics' latest earnings report can be read online. Read Transcript How much revenue does Zevra Therapeutics generate each year? Zevra Therapeutics (NASDAQ:ZVRA) has a recorded annual revenue of $23.61 million. How much profit does Zevra Therapeutics generate each year? Zevra Therapeutics (NASDAQ:ZVRA) has a recorded net income of -$105.51 million. ZVRA has generated -$0.21 earnings per share over the last four quarters. What is Zevra Therapeutics' EPS forecast for next year? Zevra Therapeutics' earnings are expected to grow from ($1.95) per share to $0.20 per share in the next year. More Earnings Resources from MarketBeat Related Companies Sarepta Therapeutics Earnings Date CG Oncology Earnings Date Adaptive Biotechnologies Earnings Date ANI Pharmaceuticals Earnings Date Arcutis Biotherapeutics Earnings Date Vericel Earnings Date Beam Therapeutics Earnings Date Dyne Therapeutics Earnings Date Apogee Therapeutics Earnings Date Twist Bioscience Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B ContractBrinker Serves Up Earnings Beat, Sidesteps Cost PressuresWhy BigBear.ai Stock's Dip on Earnings Can Be an Opportunity CrowdStrike Faces Valuation Test Before Key Earnings ReportPost-Earnings, How Does D-Wave Stack Up Against Quantum Rivals? This page (NASDAQ:ZVRA) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zevra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zevra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access